Currently, the growing population of the elderly is one of biggest problems in terms of increase in geriatric diseases. Lack of data\nfromlarge prospective studies on geriatric breast cancer patients often makes it difficult for clinicians to make treatments decisions\nfor them. Because both benefit and risk of treatment should be taken into account, treatment is usually determined considering life\nexpectancy or comorbidities in elderly patients. Treatment of breast cancer is differentiated according to histologic classifications,\nand hormone therapy is even adopted for patients with metastatic breast cancer if tumor tissue expresses hormone receptors.\nEndocrine therapy can offer great benefit to elderly patients considering its equivalent efficacy to chemotherapywith fewer toxicities\nif it is appropriately used. Aromatase inhibitors are usually prescribed agents in hormone therapy for elderly breast cancer patients\ndue to their physiology after menopause. Here, endocrine therapy for elderly patients with breast cancer in neoadjuvant, adjuvant,\nand palliative setting is reviewed along with predictive adverse events resulting from the use of hormone agents.
Loading....